The OlympiAD clinical trial randomly assigned patients with advanced HER2-negative breast cancer and a germlineBRCA mutation to a PARP inhibitor, olaparib (300 mg twice daily), or standard physician’s choice chemotherapy59. Here, ERBB2 is linked to breast cancer.